Risk Factors for No-Reflow in Patients with ST-Elevation Myocardial Infarction Who Underwent Percutaneous Coronary Intervention: A Case-Control Study

经皮冠状动脉介入治疗后ST段抬高型心肌梗死患者发生无复流的危险因素:一项病例对照研究

阅读:1

Abstract

METHODS: This case-control study retrospectively reviewed the medical data of patients treated with primary percutaneous coronary intervention within 12 h after STEMI onset between January 2010 and January 2013 at the Department of Cardiology of the Beijing Anzhen Hospital. RESULTS: A total of 902 patients were included in the analysis. The basic characteristics between the reflow and no-reflow groups were similar, except for time-to-hospital admission, heart rate, plasma glucose, high-sensitivity C-reactive protein (hsCRP)/prealbumin (PAB), neutrophil count, intraaortic balloon pump, and aspiration thrombectomy. The multivariable analysis showed that hsCRP/PAB (OR = 1.003, 95% CI: 1.000-1.006, P=0.022), neutrophil count (OR = 1.085, 95% CI: 1.028-1.146, P=0.003), plasma glucose levels (OR = 1.086, 95% CI: 1.036-1.138, P=0.001), diabetes mellitus (OR = 0.596, 95% CI: 0.371-0.958, P=0.033), Killip classification >1 (OR = 2.002, 95% CI: 1.273-3.148, P=0.003), intraoperative intraaortic balloon pump (IABP) use (OR = 3.257, 95% CI: 1.954-5.428, P=0.001), and aspiration thrombectomy (OR = 3.412, 95% CI: 2.259-5.152, P=0.001) were independently associated with no-reflow. CONCLUSION: hsCRP/PAB, neutrophil count, plasma glucose levels, diabetes mellitus, Killip classification, intraoperative IABP use, and aspiration thrombectomy were independent risk factors for no-reflow in patients with STEMI.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。